Upregulation of LINC00665 Correlates with Aggressive Hepatocellular Carcinoma and Poor Prognosis.

INTRODUCTION

Recent research has revealed that LINC00665 is crucial for cancer cell proliferation and metastasis. Despite its presence, the role of LINC00665 in diagnosing and predicting outcomes in HCC remains poorly studied.

METHODS

This study analyzed LINC00665 expression in TCGA and GTEx datasets and examined its association with clinicopathological characteristics. The association between LINC00665 and HCC prognosis was examined through survival and Cox regression analyses. To investigate the pathways associated with LINC00665 in HCC, we conducted GSEA. Additionally, the association between LINC00665 and immune cell infiltration was assessed through a comprehensive immune landscape analysis. Finally, multiple in vitro experiments validated the function of LINC00665 in accelerating HCC progression.

RESULTS

Our study demonstrated a significant upregulation of LINC00665 in hepatocellular carcinoma (HCC). Elevated LINC00665 expression was strongly associated with adverse clinicopathological features, poor prognosis, and an immunosuppressive tumor microenvironment. Gene set enrichment analysis (GSEA) revealed that LINC00665 participates in multiple established oncogenic pathways. Furthermore, we observed noTable alterations in immune cell populations associated with its expression. Functional assays showed that silencing LINC00665 significantly inhibited tumor cell proliferation and invasive potential, highlighting its role as a potential therapeutic target in HCC.

DISCUSSION: This study establishes LINC00665 as a critical oncogenic driver and prognostic biomarker in HCC, closely associated with tumor proliferation, metastasis, and an immunosuppressive microenvironment. While these findings underscore its clinical significance, further experimental and clinical validation is necessary to translate this insight into effective therapeutic strategies.

CONCLUSIONS

To sum up, LINC00665 has potential as an oncogenic biomarker in several cancers, underscoring the need for further study.